Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

NEW YORK, N.Y., December 5, 2016 – Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment) trial demonstrating superiority of BOSULIF® (bosutinib) over imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). The study met its primary endpoint of major molecular response (MMR) at 12 months. No new or unexpected safety issues were identified. BOSULIF is currently indicated in the U.S. and EU for the treatment of adult patients with Ph+ CML with resistance or intolerance to prior therapy.

Read More

Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

London, UK, September 15, 2015 – Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called “BFORE,” which is designed to assess the effectiveness and safety of BOSULIF® (bosutinib) as a first-line treatment fopatients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemi(CML). The first patient was dosed on July 22, 2014 and the final patient was enrolled September 8, 2015.

Read More


Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer

Avillion LLP, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates, from Phase 3 clinical development to marketing approval, announced it has appointed Dr Allison Jeynes-Ellis MB, ChB, FFPM as Chief Executive Officer (CEO). Dr Jeynes-Ellis has over 20 years of senior leadership experience in the pharmaceutical industry. She has managed both large and small teams focusing on global clinical development projects that have led to new drug approvals in Europe and the USA, across a range of therapeutic areas. Dr Jeynes-Ellis is a founding member of Avillion’s management team and was formerly the company’s Chief Medical Officer.

Read More


Avillion adds Ted W. Love to board

Avillion LLP, which focuses on clinical co-development of therapeutics, today announced that Ted W. Love, M.D has been appointed a non-executive director of the business.

Read More